Maria Fardis - 09 Jun 2022 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Director
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
09 Jun 2022
Net transactions value
$0
Form type
4
Filing time
10 Jun 2022, 17:37:48 UTC
Next filing
09 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Stock Option (Right to Buy) Award $0 +24,000 $0.000000 24,000 09 Jun 2022 Common Shares 24,000 $71.70 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on June 9, 2022 with respect to 24,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments.